CytoDyn announces first patient enrolled in Phase 2 study for NASH
- NEWS RELEASE
CytoDyn (USA, KY) announced on 2 December, 2020, the first patient first visit metric was met for the Phase 2 study for NASH.
For detailed information, see the below URL.
Leronlimab is a CCR5 agonist.
We are looking forward to clinical results.